Gilotrif gets FDA priority review for uncommon EGFR mutations in advanced NSCLC
The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)